Roth MKM raised the firm’s price target on ChromaDex (CDXC) to $8 from $6 and keeps a Buy rating on the shares. The company’s Q3 results handily beat estimates and demonstrate progress in pursuing new verticals targeted earlier in 2024, including Niagen+, Ataxia, and Parkinson’s, the analyst tells investors in a research note. The firm adds that it has greater confidence now in the company’s ability to capitalize on these opportunities.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDXC: